Maintenance Hormone Therapy With Fulvestrant After First-Line Chemotherapy for Postmenopausal Hormone-receptor-positive (HR) Positive Advanced Breast Cancer: A Multicenter, Prospective Phase II Study
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2018
Price : $35 *
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms FANCY
- 07 Jul 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 02 Jun 2017 Primary endpoint (Clinical Benefit Rate) has been met,according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.